Landscape analysis
Two structural facts define the field. First, the highest-value IP is not raw-plant IP; it sits on new chemical entities, isotopologues, salts/polymorphs, and delivery systems. That is why the strongest granted U.S. positions cluster around mitragynine-class opioid receptor modulators and C11-modified analogs, while 3-deuteromitragynine and its salt forms are protected in later continuation-style filings. The claims are usually framed around pain, mood/anxiety disorders, opioid-use / withdrawal indications, or, more selectively, alcohol use disorder.
Second, a broad composition family filed by Caamtech functions almost like a catch-all purified-alkaloid platform. It expressly lists many kratom constituents, including mitragynine, 7-hydroxymitragynine, paynantheine, speciociliatine, speciogynine, mitraphylline, and others, but the family is broad and combinatorial rather than a marker that each listed alkaloid has its own dedicated drug-development program. The original U.S. case was abandoned, while a later continuation remained pending in the retrieved record.
Within the papers, the most actionable non-mitragynine signals are narrower. Speciociliatine is being revisited as a meaningful μ-opioid partial agonist and circulating metabolite; paynantheine and speciogynine stand out for serotonergic activity and as scaffolds for δ-opioid-leaning alcohol-use-disorder derivatives; mitraphylline is present in kratom chemistry and ADME studies but does not, in the retrieved English primary sources, anchor a comparably mature therapeutic IP track.
Alkaloid and derivative table
Rows are ordered from the strongest compound-specific IP programs to broader or earlier-stage research coverage. Where the retrieved source did not expose a date or definitive national-phase status, it is marked unspecified.
Dedicated programs and derivative classes
| Alkaloid / derivative | Claimant(s) | Patent or application numbers, jurisdiction, status, dates | Intended use / indication | Development stage | Key claims or mechanism from patent / paper | Primary sources |
|---|---|---|---|---|---|---|
| Mitragynine; also MG, (-)-mitragynine; C23H30N2O4; structure in PubChem CID 3034396 | Kures; Syncotrance; University of Florida group / UFRF; NIDA clinical program | WO2022234524A1 (PCT, ceased; priority 2021-05-06, filed 2022-05-06, pub 2022-11-10) plus named national phases incl. US20240239798A1, GB2623043A, EP4351573A1; US20230364172A1 (US, abandoned; priority 2022-05-14, filed 2023-05-15, pub 2023-11-16) with continuation US20240366702A1 (pending, filed 2024-03-18, publication date unspecified in retrieved source); WO2024092269A1 (WIPO, published; priority 2022-10-28, pub 2024-05-02); NCT07204171 (ClinicalTrials.gov, Phase 1 oral MG001; sponsor NIDA). | Formulation / CMC, improved oral bioavailability, palatability, solubility, and controlled oral delivery; clinical safety/PK for purified mitragynine formulation. | Clinical Phase 1 for MG001; otherwise formulation / preclinical. | Patents emphasize salts/crystalline forms of mitragynine and phospholipid or oral-bioavailability formulations. Papers characterize mitragynine as a low-efficacy / partial MOR agonist and atypical opioid scaffold rather than a conventional opioid full agonist. | PubChem structure; salts/polymorphs family; Syncotrance formulation; UF formulation; ClinicalTrials.gov study. |
| 7-Hydroxymitragynine; also 7-HMG, 7-OH, 7-OH-MIT; C23H30N2O5; structure in PubChem | Individual inventors; early Chinese academic synthesis filing; also listed in broad composition family | CN106967067A (China, pending; priority/filed 2017-05-25, pub 2017-07-21); US12492201B1 (US, active/granted; priority 2024-05-15, filed 2025-02-13, pub/grant 2025-12-09; priority claimed from US12466830B1 path). | Primarily manufacturing / purification IP; research papers tie the compound to analgesia / pain signaling as mitragynine’s active metabolite. | Preclinical / unknown as a therapeutic development program in retrieved primary sources. | Patent claims cover conversion of mitragynine to high-purity 7-OH via routes including PIFA oxidation, Fenton chemistry, CYP450-mediated conversion, or enzyme/light-assisted conversion. The 2019 ACS Central Science paper identifies 7-OH as an active metabolite of mitragynine and a key mediator of its analgesic effect via μ-opioid receptor signaling. | PubChem; CN106967067A; US12492201B1; ACS Cent. Sci. 2019. |
| Mitragynine pseudoindoxyl; also MP; C23H30N2O5; structure in PubChem | Memorial Sloan Kettering family; later Columbia / MSK / RFMH C11 family | Core early family WO2016176657A1 (PCT, ceased; priority 2015-04-30, filed 2016-04-29, pub 2016-11-03); granted national phases listed as US11046692B2, EP3291676B1, CA2983314C; later continuation US20220024923A1 (filed 2021-06-24, pending in retrieved family listing). | Analgesia / pain; scaffold optimization for atypical opioid activity. | Preclinical. | The associated paper reports that conversion from the indole to spiro-pseudoindoxyl form markedly increases opioid-receptor affinity; the pseudoindoxyls showed promise as potent analgesics with MOR agonism / DOR antagonism. Later analog IP also claims C11-substituted pseudoindoxyls. | PubChem; WO2016176657A1 family; J. Med. Chem. 2016. |
| 3-Deuteromitragynine; also 3-DM; deuterated mitragynine analog; structure in patent figures | Columbia / RFMH / Memorial Sloan Kettering; Kures | WO2020160280A1 (PCT, ceased; priority 2019-02-01, filed 2020-01-30, pub 2020-08-06); country-status lines in the retrieved family page show US17/427,502 pending, CA3128726A pending, CN202080024396.7A pending, JP2021544618A pending, EP withdrawn, AU abandoned, KR ceased; follow-on WO2022234524A1 (PCT, ceased; priority 2021-05-06, filed 2022-05-06, pub 2022-11-10) claims salts and polymorphs of mitragynine and 3-DM. | Patents state pain, depressive / anxiety / mood disorders, substance-use disorders, opioid use disorder / withdrawal, alcohol use disorder, and physicochemical / purification improvements. | Preclinical. | The deuterated family claims that deuteration attenuates formation of toxic 3-dehydromitragynine (DHM) while preserving formation of the active 7-OH metabolite; the later Kures family adds salt / crystalline-form claims for manufacturability and properties. | WO2020160280A1 family; WO2022234524A1 family. |
| C11-substituted mitragynine-family analogs; includes C11-modified analogs of mitragynine, 7-hydroxymitragynine, mitragynine-ethylene glycol adduct, and mitragynine pseudoindoxyl | Columbia / RFMH / Memorial Sloan Kettering | WO2020037136A1 (PCT, ceased; priority 2018-08-16, filed 2019-08-15); US11760758B2 (US, active/granted; filed 2021-02-16, grant/pub 2023-09-19); EP3836924A1 (EP, withdrawn in retrieved family record). | Pain, mood disorders, substance use disorders, including claims mentioning opioid addiction / withdrawal symptoms. | Preclinical. | The family claims that C11 substitution unexpectedly tunes opioid-receptor efficacy across MG, 7-OH, MG-EG, and pseudoindoxyl scaffolds, giving medicinal chemists a way to fine-tune receptor signaling rather than simply increase potency. | US11760758B2 / WO2020037136A1; site-selective C–H functionalization paper. |
| Mitragynine-class opioid receptor modulators; broader Columbia family covering mitragynine-alkaloid-derived modulators, including deuterium-enriched embodiments | Columbia | WO2017165738A1 (PCT, ceased; priority 2016-03-25, filed 2017-03-24, pub 2017-09-28); search-result family lines show US10961244B2 (granted 2021-03-30) and US11912707B2 (granted 2024-02-27). | Pain, depressive disorder, mood disorder, anxiety disorder; combination claims with NMDAR antagonists, NK antagonists, and DOR agonists. | Preclinical. | The patent family positions the mitragynine scaffold as a source of opioid receptor modulators with psychiatric and analgesic claims, and it explicitly mentions deuterium-enriched embodiments. Analytically, this family looks like a foundational bridge between the earlier analog work and the later C11/deuterated branches. | WO2017165738A1; grant listings; 2016 receptor-signaling / scaffold paper. |
Natural minor alkaloids and focused derivative leads
| Alkaloid / derivative | Claimant(s) | Patent or application numbers, jurisdiction, status, dates | Intended use / indication | Development stage | Key claims or mechanism from patent / paper | Primary sources |
|---|---|---|---|---|---|---|
| Paynantheine; C23H28N2O4; structure in PubChem CID 3037629 | Caamtech broad composition family; Columbia / Purdue / UHSP alcohol-use-disorder program | Broad-composition coverage in WO2021076849A1 (PCT, ceased; priority 2019-10-16, filed 2020-10-16, pub 2021-04-22) → US20210113644A1 (abandoned) → continuation US20230355701A1 (pending, filed 2023-07-14); appears as a natural lead / precursor in US20230250098A1 (pending; priority 2021-10-04, filed 2022-10-04, pub 2023-08-10). | Broad-family claims: psychological / compulsive / depressive disorders in combination settings; later derivative program: alcohol use disorder. | Preclinical as an isolated lead; current human work is broader kratom PK rather than isolated paynantheine dosing. | Papers show high 5-HT1A and 5-HT2B affinity and relatively reduced μ-opioid potency versus mitragynine; the AUD patent uses paynantheine as a natural scaffold, then oxidizes it toward 7-hydroxypaynantheine. | PubChem; Caamtech family; AUD patent; serotonin-receptor paper; clinical kratom study listing. |
| Speciogynine; C23H30N2O4; structure in PubChem CID 15560577 | Caamtech broad composition family; Columbia / Purdue / UHSP alcohol-use-disorder program | Same broad-composition family as above (WO2021076849A1 → US20210113644A1 abandoned → US20230355701A1 pending continuation); appears in US20230250098A1 as a natural lead for AUD derivatives. | Broad-family combination claims; later program specifically points to alcohol use disorder. | Preclinical as an isolated lead. | Papers show strong serotonin-receptor activity (especially 5-HT1A / 5-HT2B relative to mitragynine). In the AUD patent/paper stream, 7-hydroxyspeciogynine emerges as the more explicit lead compound. | PubChem; Caamtech family; AUD patent; serotonin paper. |
| Speciociliatine; diastereomer of mitragynine; C23H30N2O4; structure in PubChem CID 15560576 | Caamtech broad composition family; Columbia / Purdue / UHSP AUD program (comparative / lead-finding role) | Broad-composition coverage in WO2021076849A1 / US20210113644A1 / US20230355701A1; appears in US20230250098A1 as one of the natural kratom alkaloids evaluated for improved AUD leads. | Broad-family combination claims; comparative / exploratory role in AUD medicinal chemistry. | Preclinical; actively researched in metabolism and receptor studies. | Recent papers characterize speciociliatine as a μ-opioid partial agonist and report higher MOR binding affinity than mitragynine in at least one study; it is also reported as a major circulating metabolite / exposure species after kratom administration. | PubChem; Caamtech family; speciociliatine metabolism paper; newer opioid-receptor paper. |
| Hydroxylated corynantheine-type derivatives; especially 7-hydroxyspeciogynine and 7-hydroxypaynantheine; structures shown in patent figures | Columbia / Purdue / UHSP AUD program | US20230250098A1 (US, pending; priority 2021-10-04, filed 2022-10-04, pub 2023-08-10). | Alcohol use disorder. | Preclinical. | The patent states that the program sought kratom-derived compounds with greater δ-opioid receptor modulation relative to μ-opioid receptor modulation. It explicitly says 7-hydroxyspeciogynine was an effective lead compound with a limited side-effect profile. | AUD patent; supporting paper thread. |
| Mitraphylline; oxindole alkaloid; C21H24N2O4; structure in PubChem CID 94160 | Broad-composition family only in retrieved English IP (Caamtech) | Included in WO2021076849A1 / US20210113644A1 / US20230355701A1 broad purified-kratom composition family. A separate, dedicated mitraphylline therapeutic family was not identified in the retrieved English primary sources. | Broad-family combination claims are present; direct compound-level therapeutic use remains unspecified in retrieved patents. | Preclinical / unknown. | Kratom-specific papers place mitraphylline in ADME work and later Thai Mitragyna phytochemistry / opioid-gene-expression studies. The retrieved patent record shows it being listed inside a broad kratom composition family rather than as a named lead asset. | PubChem; ADME paper; broad composition family; 2025 Mitragyna paper. |
Active researchers and organizations
The most durable medicinal-chemistry cluster runs through Columbia University, Memorial Sloan Kettering Cancer Center, and the Research Foundation for Mental Hygiene, with recurrent appearances by Andrew Kruegel, Dalibor Sames, Jonathan Javitch, and Susruta Majumdar across the opioid-modulator, C11-analog, and deuterated-mitragynine families. This cluster is the clearest example of a coherent scaffold-optimization strategy rather than simple natural-product repackaging.
On the translational side, the most visible public-sector axis is National Institute on Drug Abuse together with University of Florida, where Christopher McCurdy and Abhisheak Sharma appear repeatedly in grants, symposium reporting, analytical work, and kratom / mitragynine translational programs. The NIDA pipeline page explicitly lists MG001 (mitragynine), and UF reporting highlights continued NIDA-funded kratom science.
Other active players visible in the retrieved record include Purdue University and University of Health Sciences & Pharmacy in St. Louis in the alcohol-use-disorder derivative program, along with Kures Inc in the deuterated / salt-form branch, Caamtech Inc in the broad purified-composition branch, Syncotrance LLC in oral / buccal delivery, and Fuzhou University in an early 7-hydroxymitragynine synthesis patent.
Timeline
The timeline below follows the main filing, publication, and paper milestones reflected in the retrieved primary sources.
timeline
title Selected kratom-alkaloid patent and publication milestones
2014-05 : ADME paper on mitragynine, 7-OH, and mitraphylline
2015-04 : Priority for mitragynine analogs / pseudoindoxyl family
2016-03 : Priority for mitragynine alkaloids as opioid receptor modulators
2018-08 : Priority for C11-substituted mitragynine-family analogs
2019-02 : Priority for deuterated mitragynine analogs
2019-06 : Paper identifies 7-OH as active metabolite mediating mitragynine analgesia
2019-10 : Broad purified-kratom composition family filed
2021-10 : Alcohol-use-disorder derivative patent priority
2022-05 : Salts / polymorphs of mitragynine and 3-DM PCT filed
2024-05 : UF oral-bioavailability kratom formulation PCT published
2025-10 : Phase 1 oral MG001 appears on ClinicalTrials.govBottom-line assessment
The field is not evenly distributed across kratom alkaloids. The commercially serious IP is overwhelmingly aimed at mitragynine-centered medicinal chemistry and mitragynine-centered formulations, not at the whole kratom alkaloid set. 7-Hydroxymitragynine and mitragynine pseudoindoxyl are the main potency-driving derivative nodes; 3-deuteromitragynine represents the clearest isotopologue strategy; and the most explicit minor-alkaloid translational use case so far is the alcohol-use-disorder program built from paynantheine, speciogynine, speciociliatine, and especially 7-hydroxyspeciogynine.
Taken together, the retrieved record suggests a simple hierarchy. Mitragynine is the clear translational front-runner because it already has formulation IP and a Phase 1 clinical listing. 7-OH and pseudoindoxyl are the most important semisynthetic / metabolite scaffolds for potency and receptor-bias questions. Paynantheine, speciogynine, speciociliatine, and mitraphylline remain scientifically important, but today they function more as pharmacology leads, biomarkers, or broad-composition inclusions than as independently mature patented drug programs.